Literature DB >> 9805212

Review of available instruments and methods for assessing quality of life in anti-anginal trials.

B D Bliven1, C P Green, J A Spertus.   

Abstract

Collection of patient-centred health status is a method for quantifying patient outcome in the context of clinical trials for the treatment of coronary artery disease (CAD). Traditional clinical trial end-points, such as morbidity and mortality, fail to adequately measure the health-related outcomes of disease states for which death is a rare occurrence. Health-related quality of life (QOL) and functional status surveys allow measurement of the general, and/or disease-specific, health-related limitations experienced by patients. Measures of patient preference, in turn, quantify the effects these health-related limitations have on the overall value patients ascribe to their current health state. Together, these outcomes measures may provide a more accurate appraisal of the benefit conferred by treatment. Currently, selection of the appropriate outcomes measures and methodological approaches for a clinical trial is complicated by the lack of consensus on a single quality of life measure for use with patients with (CAD). This article outlines the use of QOL measures in anti-anginal trials done to date and summarises the approaches currently available for assessing QOL, including the differences between psychometric and preference-based techniques, and general and disease-specific health measures. In conclusion, a framework is provided for selecting the appropriate instruments and methodology in the context of the clinical trial.

Entities:  

Mesh:

Year:  1998        PMID: 9805212     DOI: 10.2165/00002512-199813040-00007

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  32 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index.

Authors:  C L Nelson; J E Herndon; D B Mark; D B Pryor; R M Califf; M A Hlatky
Journal:  Am J Cardiol       Date:  1991-10-01       Impact factor: 2.778

3.  A summary index for the assessment of quality of life in angina pectoris.

Authors:  A Wilson; I Wiklund; T Lahti; M Wahl
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

4.  Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. The Coronary Artery Surgery Study (CASS)

Authors:  W J Rogers; C J Coggin; B J Gersh; L D Fisher; W O Myers; A Oberman; L T Sheffield
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

5.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

6.  Health-related quality of life in persons with acquired immune deficiency syndrome.

Authors:  P D Cleary; F J Fowler; J Weissman; M P Massagli; I Wilson; G R Seage; C Gatsonis; A Epstein
Journal:  Med Care       Date:  1993-07       Impact factor: 2.983

7.  Measuring functional outcomes in chronic disease: a comparison of traditional scales and a self-administered health status questionnaire in patients with rheumatoid arthritis.

Authors:  R A Deyo; T S Inui; J D Leininger; S S Overman
Journal:  Med Care       Date:  1983-02       Impact factor: 2.983

8.  Monitoring the quality of life in patients with coronary artery disease.

Authors:  J A Spertus; J A Winder; T A Dewhurst; R A Deyo; S D Fihn
Journal:  Am J Cardiol       Date:  1994-12-15       Impact factor: 2.778

9.  Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)

Authors:  N Rehnqvist; P Hjemdahl; E Billing; I Björkander; S V Eriksson; L Forslund; C Held; P Näsman; N H Wallén
Journal:  Eur Heart J       Date:  1996-01       Impact factor: 29.983

10.  Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.

Authors:  D J Cohen; J A Breall; K K Ho; R E Kuntz; L Goldman; D S Baim; M C Weinstein
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

View more
  2 in total

1.  Health-related quality of life in patients with coronary artery disease treated for angina: validity and reliability of German translations of two specific questionnaires.

Authors:  S Höfer; W Benzer; G Schüssler; N von Steinbüchel; N B Oldridge
Journal:  Qual Life Res       Date:  2003-03       Impact factor: 4.147

Review 2.  Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.

Authors:  Greg L Plosker; Tim Ibbotson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.